Exploring senior RWE / pharmacoepidemiology / HEOR roles at pharma, RWE platform vendors, and CROs — particularly those that combine observational methodology with platform engineering.
Top targets: Aetion, Flatiron Health, TriNetX, Tempus (RWE platform companies); Genmab, J&J, Pfizer, Novartis (pharma); IQVIA, Evidera, ICON (CROs).
Methods & research
Building svy-causal — the survey-weighted causal inference module of the svy ecosystem. IPTW, stabilized weights, doubly robust estimation, validated against NHANES.
Poster accepted at ISPE 2026 (Milan, August 29 – September 2): "Design-Based Causal Inference for Pharmacoepidemiology: Survey-Weighted IPTW and Doubly Robust Estimation in Python With NHANES Validation."
Studying ICH E9(R1), the FDA RWE framework guidance, and ISPE Good Pharmacoepidemiology Practices.
Platform
svyLab is at 327 passing tests and approaching public preview. Three hardening phases done; the lifecycle/classification authority model is settled. Currently finishing the dataset detail page redesign and the demo seed data for Ministry-of-Health and UN-agency demo orgs.
Frontend in Astro + Svelte 5; backend in Python (Litestar) + PostgreSQL + DuckDB + Redis; AI layer via svy-agents.
Consulting
Selectively. Recently completed: NBS Tanzania capacity assessment for the World Bank / SADC. INSBU Burundi small area estimation training (2 weeks). FeeLoST DHIS2-integrated platform for Ethiopia's Ministry of Health.
Open to short-term technical assistance on survey design, small area estimation, or RWE infrastructure questions. English or French.
Reading & thinking about
Target trial emulation in observational RWD; marginal structural models; competing risks under complex sampling.
How RWE platforms (Aetion, Flatiron, etc.) handle reproducibility, audit trails, and AI-assisted analysis. Where svyLab's design overlaps and where it differs.
The slow but accelerating convergence between survey-design-based inference and pharmacoepidemiology methods.
If something here resonates with what you're working on,
get in touch
.